To the Editor-Over the past few years, there has been substantial controversy regarding whether HIV-1/hepatitis C virus (HCV)-coinfected individuals experience more-rapid HIV-1 disease progression than do HIV-1-monoinfected individuals [1] [2] [3] . Yoo et al., in a cohort of largely untreated young HIV-1/HCV-coinfected participants with hemophilia who were followed for 7 years, observed lower CD4 + T cell counts and a higher risk of AIDS-related mortality in the participants infected with HCV genotype 1 than in the participants infected with other genotypes [4] . However, as was suggested by the authors, the peculiar characteristics of the participants make the results of the study not directly applicable to other coinfected groups.
We repeated the analysis of Yoo et al. using the CD4 + T cell counts and HIV-1 RNA loads recorded in the Italian Cohort Naive for Antiretrovirals (I.Co.N.A.) database over the period during which the patients remained untreated. The I.Co.N.A. is a multicenter, prospective, observational study cohort that includes HIV-1-infected adults who were antiretroviral naive at the time of enrollment [5] . Specifically, we created an age-adjusted random coefficient linear regression model with CD4 + T cell count as the response variable [6] . We then further adjusted for HCV RNA loads measured in plasma that had been obtained and stored before the initiation of therapy. Mean CD4 + T cell counts were compared overall across the HCV genotype groups as well as between groups by the construction of prespecified contrasts.
Our analysis focused on 302 adult pa- To our knowledge, in the era of potent combination antiretroviral therapy (cART), it remains unclear whether the response to therapy may substantially differ between HIV-1/HCV-coinfected and HIV-1-monoinfected individuals [5, 8, 9] . Interestingly, in another recent investigation conducted in a group of HCV-viremic coinfected patients in the I.Co.N.A. who were initiating cART, we did not find a clear association between HCV genotype and the probability of a CD4 + T cell count response to their first treatment [10] . However, even if an association between HCV genotype 1 and CD4 + T cell count decay really does exist in untreated HIV-1 populations, it is possible that the same association may not be seen when comparing the CD4 + T cell count rise after cART initiation. Further investigations aimed at better understanding the intimate mechanisms by which HCV alters HIV-1 disease 
